British-Swedish pharma company AstraZeneca, which is working with Oxford University on a coronavirus vaccine, is looking to test two high doses of its experimental vaccine in later-stage trials. “Right now, the safe thing to do is go with two doses, and then we'll start exploring single doses or lower doses," Mene Pangalos, Executive VP for BioPharmaceuticals R&D at AstraZeneca said.